-

Eurofins: Weekly Report on Share Repurchases From 22nd September to 26th September 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News:

Eurofins (Paris:ERF):

Name of the Issuer

Identify code of the Issuer

Transaction day

Identify code of the financial instrument

Total daily volume (in number of shares)

Daily weighted average purchase price of the shares

Market (MIC Code)

EUROFINS SCIENTIFIC

529900JEHFM47DYY3S57

22/09/2025

FR0014000MR3

10 000

62.5592

XPAR

EUROFINS SCIENTIFIC

529900JEHFM47DYY3S57

23/09/2025

FR0014000MR3

10 000

62.5362

XPAR

EUROFINS SCIENTIFIC

529900JEHFM47DYY3S57

24/09/2025

FR0014000MR3

10 000

62.0072

XPAR

EUROFINS SCIENTIFIC

529900JEHFM47DYY3S57

25/09/2025

FR0014000MR3

10 000

60.9076

XPAR

EUROFINS SCIENTIFIC

529900JEHFM47DYY3S57

26/09/2025

FR0014000MR3

10 000

61.1093

XPAR

 

 

 

TOTAL

50 000

61.8239

 

Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) N° 596/2014 (the Market Abuse Regulation) a full breakdown of the individual trades are disclosed on Eurofins Scientific SE website: https://www.eurofins.com/investors/share-buy-back-programmes

Contacts

Eurofins

Eurofins

BOURSE:ERF
Release Versions
English

Contacts

Eurofins

More News From Eurofins

Eurofins Launches Seventh Buy-Back Programme of Its Own Shares

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (the “Company”) (EUFI.PA) (Paris:ERF) announces its intention to launch a new buy-back programme of its own shares (ISIN FR0014000MR3) for a maximum amount representing up to 4.5% of its share capital. The maximum amount meant for the repurchase of the Company’s shares may not exceed a sum corresponding to an amount equivalent to the value of 4.5% of the shares composing the share capital of the Company as of the Board of Dire...

Eurofins Achieves Organic Growth of 2.6% in Q1 2026, Including Impact of Exceptionally Severe Weather; 2026 and Mid-Term Objectives Reiterated

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: The Eurofins (Paris:ERF) network of companies delivered steady growth despite significant temporary headwinds: Reported revenues in Q1 2026 totalled €1,789m, an increase of 1.3% vs Q1 2025. This was driven by both organic growth13 and acquisitions, with a -4.8% headwind from foreign exchange as the Euro strengthened against most currencies compared to the prior year quarter. Organic revenue growth13 in Q1 2026 was 2.6%, which includes a +0.1% adjust...

Eurofins CDMO Alphora Announces Integration of Advanced Continuous Flow Technology in API Manufacturing

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Eurofins CDMO Alphora is excited to announce the expansion of its Active Pharmaceutical Ingredient (API) manufacturing capabilities through the integration of advanced, custom-built Continuous Flow (CF) technology to its operations. The company is receiving advisory services and research and development funding support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) for this project. Developed in-house by Euro...
Back to Newsroom